R&D chief: Brintellix data are highly significant
Danish pharma group Lundbeck has published new data on its recently approved antidepressant Brintellix. The data puts the potential blockbuster in a very special position, says Lundbeck's head of R&D.
by Benjamin Werner Christensen
If Lundbeck and the group’s Japanese partner Takeda manage to secure a label that speaks of cognitive improvements for antidepressant Brintellix, the drug would be so different from current antidepressants on the market that it could become a multiple blockbuster, according to several analysts.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Lundbeck could reach 2020 targets, but…
For abonnenter
Bleak years ahead for Lundbeck
For abonnenter
Lundbeck: This is our focus for 2014 and 2015
For abonnenter
